Rezafungin: A Novel Antifungal for the Treatment of Invasive Candidiasis
Young Yoon Ham, James S. Lewis, George R. Thompson
Abstract
isolates. Available clinical data show robust safety and promising efficacy. Phase III trials will provide data on efficacy of rezafungin for the treatment of candidemia and invasive candidiasis and for the prevention of invasive fungal disease in blood and bone marrow transplant recipients. Rezafungin is a promising new candidate in the antifungal arsenal that opens up clinical possibilities based on its impressive half-life, such as early hospital discharge for stable patients and use as prophylaxis in immunocompromised patients.
Topics & Concepts
EchinocandinCandida aurisEchinocandinsInvasive candidiasisMedicineDosingAntifungalAntifungal drugsAzoleAspergillusIntensive care medicineClinical trialMicrobiologyAmphotericin BInternal medicineBiologyCaspofunginDermatologyFluconazoleAntifungal resistance and susceptibilityFungal Infections and StudiesNematode management and characterization studies